Can High-Dose amoxicillin be made safer?

NCT ID NCT04070469

Completed Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study looks at patients receiving high-dose intravenous amoxicillin for serious bacterial infections. Researchers will measure drug levels in the blood during the first week to see how much they vary between patients and within the same patient. They will also check for side effects like kidney problems (crystalluria) and aim to identify factors linked to overdose. The goal is to gather information that could lead to safer, more personalized dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: amoxicillin
What this could lead to: If successful, this could help define safer dosing targets for high-dose amoxicillin, reducing kidney and neurological side effects in serious infections.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate practice changes, and individual responses vary widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTION, BACTERIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease Crystalluria Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTION, BACTERIAL

Contacts and locations

Locations

CHU Clermont-Ferrand

Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.